Insta
Serum Institute’s Covishield Vaccine Produces Antibodies Against B.1.617.1 Variant Of Coronavirus: ICMR Study
Oxford-AstraZeneca Covishield vaccine (Pic Via Twitter)
The Covishield Covid-19 vaccine, which is being manufactured in India by Serum Institute of India, is effective against the B.1.617.1 strain of the Coronavirus, a study has found.
The B.1.617.1 variant of the Covid-19 virus is considered to be responsible for surge of the cases in India.
A study by the Indian Council of Medical Research (ICMR) has concluded that "Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in vaccinated individuals”.
"The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1," said the study published in pre-print server bioRxiv.
Till date, over 170 million doses of vaccine have been administered to Indian citizens with two approved vaccines- Covishield (Astrazeneca-Oxford) and Bharat Biotech's Covaxin.
Earlier, the ICMR in a study has said that the indigenous Covid-19 vaccine was effective against the various strains of the Covid-19 virus including B.1.617.1, B.1.1.7, B.1.1.28.2 and variants.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
